8. ハンチントン病
[臨床試験数:197,薬物数:171(DrugBank:54),標的遺伝子数:82,標的パスウェイ数:144

Searched query = "Huntington disease", "Huntington chorea"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04478734
(ClinicalTrials.gov)
January 1, 202111/2/2020Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's DiseaseMulticentric Trial on the Use of Combined Therapy of Thiamine and Biotine in Patients With Huntington´s DiseaseHuntington DiseaseDrug: Moderate doses of Thiamine y Biotin;Drug: High doses of Thiamine y BiotinFundación Pública Andaluza para la gestión de la Investigación en SevillaCiberned (Centro de Investigación Biomédica en Red)Not yet recruiting18 YearsN/AAll24Phase 2Spain
2EUCTR2020-002822-10-DE
(EUCTR)
11/12/202006/11/2020A study of Pridopidine in Patients with Early Stage of Huntington DiseaseA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients with Early Stage of Huntington Disease - PRidopidine Outcome on Function in Huntington Disease (PROOF-HD) Huntington Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Pridopidine
Product Code: PL101
INN or Proposed INN: PRIDOPIDINE HYDROCHLORIDE
Other descriptive name: Pridiopidine
Prilenia Neurotherapeutics Ltd.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
480Phase 3United States;European Union;Canada;Germany;United Kingdom
3NCT04556656
(ClinicalTrials.gov)
October 16, 202014/9/2020PRidopidine's Outcome On Function in Huntington Disease, PROOF- HDA Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multicenter Study Evaluating the Efficacy and Safety of Pridopidine in Patients With Early Stage of Huntington DiseaseHuntington DiseaseDrug: Pridopidine;Drug: PlaceboPrileniaNULLRecruiting25 YearsN/AAll480Phase 3United States
4NCT04421339
(ClinicalTrials.gov)
October 7, 20204/6/2020Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot StudyMelatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot StudyHuntington DiseaseDietary Supplement: Melatonin;Other: PlaceboThe University of Texas Health Science Center, HoustonHuntington's Disease Society of AmericaRecruiting18 Years75 YearsAll20N/AUnited States
5EUCTR2018-003898-94-NL
(EUCTR)
01/10/202008/10/2020An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intrathecally Administered RO7234292 (RG6042) in Patients with Huntington’s DiseaseAN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH HUNTINGTON’S DISEASE Huntington's disease (HD)
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Code: Ro 723-4292/F02
INN or Proposed INN: tominersen
Other descriptive name: RG6042, formerly ISIS 443139, IONIS-HTTRx
F.Hoffmann La-Roche LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
1050Phase 3United States;Spain;Austria;Chile;Russian Federation;United Kingdom;Switzerland;Italy;France;Canada;Argentina;Poland;Australia;Denmark;Netherlands;Germany;New Zealand
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT04400331
(ClinicalTrials.gov)
September 18, 202019/5/2020Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington DiseaseOpen-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington DiseaseChorea, HuntingtonDrug: ValbenazineNeurocrine BiosciencesHuntington Study GroupEnrolling by invitation18 Years75 YearsAll120Phase 3United States
7NCT04301726
(ClinicalTrials.gov)
September 1, 202013/2/2020Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HDEfficacy of Deutetrabenazine in Huntington's Disease Patients With Dysphagia: A Randomised, Placebo-controlled Pilot StudyHuntington DiseaseDrug: Deutetrabenazine Oral Tablet [Austedo];Drug: Placebo oral tabletFundacion Huntington Puerto RicoNULLNot yet recruiting21 YearsN/AAll48Phase 1NULL
8NCT04514367
(ClinicalTrials.gov)
August 17, 202027/7/2020An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's DiseaseA Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects With, or at Risk for, Manifest Huntington's DiseaseHuntington DiseaseDrug: ANX005Annexon, Inc.NULLRecruiting18 YearsN/AAll24Phase 2United States
9NCT04201834
(ClinicalTrials.gov)
August 13, 202013/12/2019Risperidone for the Treatment of Huntington's Disease Involuntary MovementsRisperidone for the Treatment of Huntington's Disease ChoreaHuntington Disease;ChoreaDrug: Risperidone;Device: BioStamp nPoint deviceUniversity of RochesterNULLRecruiting18 Years65 YearsAll12Phase 2United States
10EUCTR2019-003637-42-DE
(EUCTR)
28/07/202009/06/2020A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s DiseaseA Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease Huntington's Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120101
Product Code: WVE-120101
INN or Proposed INN: WVE-120101
Wave Life Sciences UK LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 2France;Canada;Poland;Denmark;Australia;Germany;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2019-002178-30-DE
(EUCTR)
28/07/202012/06/2020A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients with Huntington’s DiseaseA Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients with Huntington’s Disease Huntington’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120102
Product Code: WVE-120102
INN or Proposed INN: WVE-120102
Wave Life Sciences UK LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
70Phase 2France;Canada;Poland;Denmark;Australia;Germany;United Kingdom
12EUCTR2019-003637-42-DK
(EUCTR)
06/07/202002/03/2020A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s DiseaseA Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease Huntington's Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.1;Level: LLT;Classification code 10012278;Term: Dementia due to Huntington's disease;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120101
Product Code: WVE-120101
INN or Proposed INN: WVE-120101
Wave Life Sciences UK LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 2France;Canada;Poland;Australia;Denmark;Germany;United Kingdom
13NCT04617847
(ClinicalTrials.gov)
April 13, 202030/10/2020Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's DiseaseA Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients With Huntington's DiseaseHuntington DiseaseDrug: WVE-120101Wave Life Sciences Ltd.NULLEnrolling by invitationN/AN/AAll60Phase 1;Phase 2Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
14EUCTR2019-003637-42-PL
(EUCTR)
11/04/202019/02/2020A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s DiseaseA Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120101 in Patients with Huntington’s Disease Huntington's Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120101
Product Code: WVE-120101
INN or Proposed INN: WVE-120101
Wave Life Sciences UK LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 2France;Canada;Poland;Denmark;Australia;Germany;United Kingdom
15EUCTR2019-002178-30-DK
(EUCTR)
22/01/202018/09/2019A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients with Huntington’s DiseaseA Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients with Huntington’s Disease Huntington’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.0;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120102
Product Code: WVE-120102
INN or Proposed INN: WVE-120102
Wave Life Sciences UK LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
70Phase 2France;Canada;Poland;Australia;Denmark;Germany;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT04219241
(ClinicalTrials.gov)
January 202011/12/2019Clinical Extension Study for Safety and Efficacy Evaluation of Cellavita-HD Administration in Huntington's Patients.Clinical Extension Study for Assessing the Safety and Efficacy of the Intravenous Administration of Cellavita-HD in Huntington's Disease Patients Who Participated in the ADORE-DH Study.Huntington DiseaseBiological: Cellavita-HDAzidus BrasilCellavita Pesquisa Científica LtdaNot yet recruiting21 Years65 YearsAll35Phase 2;Phase 3Brazil
17NCT04102579
(ClinicalTrials.gov)
November 13, 201923/9/2019Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington DiseaseA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington DiseaseChorea, HuntingtonDrug: Valbenazine;Drug: PlaceboNeurocrine BiosciencesHuntington Study GroupRecruiting18 Years75 YearsAll120Phase 3United States;Canada
18EUCTR2019-002178-30-PL
(EUCTR)
29/10/201913/08/2019A Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients with Huntington’s DiseaseA Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients with Huntington’s Disease Huntington’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120102
Product Code: WVE-120102
INN or Proposed INN: WVE-120102
Wave Life Sciences UK LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
70Phase 2France;Canada;Poland;Denmark;Australia;Germany;United Kingdom
19NCT04071639
(ClinicalTrials.gov)
October 20, 201926/8/2019Symptomatic Therapy for Patients With Huntington's DiseaseRandomized Clinical Trial to Evaluate the Efficacy and Safety of Symptomatic Drug Therapy for Mild to Moderate Huntington's Disease PatientsHuntington DiseaseDrug: Haloperidol;Drug: Risperidone;Drug: Zoloft;Drug: Coenzyme Q10Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNULLRecruitingN/AN/AAll100Phase 1China
20NCT04617860
(ClinicalTrials.gov)
September 24, 201930/10/2020Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's DiseaseA Multicenter, Open-label Extension Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-120102 in Patients With Huntington's DiseaseHuntington DiseaseDrug: WVE-120102Wave Life Sciences Ltd.NULLEnrolling by invitationN/AN/AAll60Phase 1;Phase 2Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT04000594
(ClinicalTrials.gov)
September 2, 201926/6/2019A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's DiseaseAn Open-Label, Adaptive Multiple-Dose Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's DiseaseHuntingtons DiseaseDrug: RO7234292 (RG6042)Hoffmann-La RocheNULLRecruiting25 Years65 YearsAll20Phase 1Netherlands;United Kingdom
22NCT03854019
(ClinicalTrials.gov)
August 5, 201922/2/2019Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's DiseaseEvaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's DiseaseHuntington Disease;IrritabilityDrug: Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg);Drug: PlaceboThe University of Texas Health Science Center, HoustonCures Within ReachRecruiting18 Years75 YearsAll22Phase 3United States
23EUCTR2018-002987-14-NL
(EUCTR)
23/07/201925/02/2019A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients with Manifest Huntington's diseaseA RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST HUNTINGTON'S DISEASE Huntington's disease (HD)
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
F.Hoffmann La-Roche LtdNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
600Phase 3United States;Spain;Austria;Russian Federation;Switzerland;United Kingdom;Italy;France;Canada;Argentina;Poland;Australia;Denmark;Netherlands;Germany;New Zealand
24EUCTR2016-005095-10-FR
(EUCTR)
11/07/201905/03/2019A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease Huntington's Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Wave Life Science Ltd.NULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
48Phase 1;Phase 2United States;France;Canada;Poland;Denmark;Australia;Germany;United Kingdom
25EUCTR2016-005142-39-FR
(EUCTR)
09/07/201921/05/2019A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s Disease Huntington’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
WAVE Life Sciences LtdNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
48Phase 1;Phase 2United States;France;Canada;Poland;Denmark;Australia;Germany;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26NCT03980938
(ClinicalTrials.gov)
July 8, 20197/6/2019Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington DiseaseA Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD)Huntington DiseaseDrug: neflamapimod;Other: PlaceboEIP Pharma IncVoisin Consulting, Inc.Recruiting30 Years70 YearsAll16Phase 2United Kingdom
27EUCTR2018-004840-51-GB
(EUCTR)
26/06/201922/03/2019Study of Neflamapimod in Early-Stage Huntington Disease (HD)A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD) Early-Stage Huntington Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
EIP Pharma, Inc.NULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
16Phase 2United Kingdom
28EUCTR2018-003898-94-ES
(EUCTR)
21/06/201911/06/2019An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intrathecally Administered RO7234292 (RG6042) in Patients with Huntington’s DiseaseAN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH HUNTINGTON’S DISEASE Huntington's disease (HD)
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Roche Farma S.A(Soc. Unipersonal) que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTDNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
900Phase 3United States;Spain;Austria;Russian Federation;Chile;Switzerland;United Kingdom;Italy;France;Canada;Argentina;Poland;Australia;Denmark;Netherlands;Germany;New Zealand
29NCT03842969
(ClinicalTrials.gov)
April 23, 201911/2/2019An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Patients Who Participated in Prior Roche and Genentech Sponsored StudiesAn Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intrathecally Administered RO7234292 (RG6042) in Patients With Huntington's DiseaseHuntington DiseaseDrug: RO7234292 (RG6042)Hoffmann-La RocheNULLRecruiting25 YearsN/AAll1100Phase 3United States;Argentina;Australia;Austria;Canada;Germany;Italy;Netherlands;Spain;United Kingdom
30EUCTR2018-002987-14-DK
(EUCTR)
11/04/201915/02/2019A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients with Manifest Huntington's diseaseA RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST HUNTINGTON'S DISEASE Huntington's disease (HD)
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
F.Hoffmann La-Roche LtdNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
800Phase 3United States;Spain;Austria;Russian Federation;Chile;Italy;Switzerland;United Kingdom;France;Canada;Argentina;Poland;Denmark;Australia;Netherlands;Germany;New Zealand;Japan;China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31EUCTR2018-002987-14-AT
(EUCTR)
27/03/201922/03/2019A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients with Manifest Huntington's diseaseA RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST HUNTINGTON'S DISEASE Huntington's disease (HD)
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
F.Hoffmann La-Roche LtdNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
600Phase 3United States;Spain;Austria;Russian Federation;Switzerland;United Kingdom;Italy;France;Canada;Argentina;Poland;Australia;Denmark;Germany;Netherlands;New Zealand
32EUCTR2018-002987-14-PL
(EUCTR)
19/03/201907/04/2020A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients with Manifest Huntington's diseaseA RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST HUNTINGTON'S DISEASE Huntington's disease (HD)
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Code: Ro 723-4292/F02
INN or Proposed INN: not available
Other descriptive name: RG6042, formerly ISIS 443139, IONIS-HTTRx
F.Hoffmann La-Roche LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
600Phase 3United States;Spain;Austria;Russian Federation;United Kingdom;Switzerland;Italy;France;Canada;Argentina;Poland;Australia;Denmark;Germany;Netherlands;New Zealand
33EUCTR2018-003898-94-GB
(EUCTR)
07/03/201913/12/2018An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intrathecally Administered RO7234292 (RG6042) in Patients with Huntington’s DiseaseAN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH HUNTINGTON’S DISEASE Huntington's disease (HD)
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Code: Ro 723-4292/F02
INN or Proposed INN: tominersen
Other descriptive name: RG6042, formerly ISIS 443139, IONIS-HTTRx
F.Hoffmann La-Roche LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
1100Phase 3United States;Spain;Austria;Russian Federation;Chile;Switzerland;United Kingdom;Italy;France;Canada;Argentina;Poland;Australia;Denmark;Germany;Netherlands;New Zealand
34NCT03787758
(ClinicalTrials.gov)
February 28, 201917/12/2018A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part BA Phase 1, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Healthy Adults With an Open-label Cohort of Patients With Huntington's DiseaseHuntington DiseaseDrug: SAGE-718Sage TherapeuticsNULLCompleted18 Years70 YearsAll6Phase 1United States
35EUCTR2016-005142-39-DK
(EUCTR)
26/02/201920/12/2018A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s Disease Huntington’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120102
Product Code: WVE-120102
INN or Proposed INN: WVE-120102
Wave Life Sciences UK LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
80Phase 1;Phase 2United States;France;Canada;Poland;Australia;Denmark;Germany;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36EUCTR2016-005095-10-DK
(EUCTR)
26/02/201920/12/2018A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease Huntington's Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120101
Product Code: WVE-120101
INN or Proposed INN: WVE-120101
Wave Life Sciences UK LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 1;Phase 2France;Canada;Poland;Australia;Denmark;Germany;United Kingdom
37EUCTR2018-002987-14-GB
(EUCTR)
13/02/201908/02/2019A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients with Manifest Huntington's diseaseA RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST HUNTINGTON'S DISEASE Huntington's disease (HD)
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
F.Hoffmann La-Roche LtdNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
600Phase 3United States;Spain;Austria;Russian Federation;United Kingdom;Switzerland;Italy;France;Canada;Argentina;Poland;Australia;Denmark;Germany;Netherlands;New Zealand
38NCT03761849
(ClinicalTrials.gov)
January 23, 201930/11/2018A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's DiseaseA Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's DiseaseHuntingtons DiseaseDrug: RO7234292;Drug: PlaceboHoffmann-La RocheNULLActive, not recruiting25 Years65 YearsAll909Phase 3United States;Argentina;Australia;Austria;Canada;Chile;Denmark;France;Germany;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Spain;Switzerland;United Kingdom;China
39NCT03764215
(ClinicalTrials.gov)
November 15, 201827/11/2018Nilotinib in Huntington's DiseaseAn Open Label, Phase Ib Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability and Biomarkers in Huntington's DiseaseHuntington DiseaseDrug: Nilotinib 150 MGGeorgetown UniversityNULLRecruiting25 Years90 YearsAll10Phase 1United States
40EUCTR2017-002471-25-GB
(EUCTR)
18/10/201804/08/2017An extension study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the study drug, RO7234292 (ISIS 443139), in patients who participated in prior investigational studies of RO7234292AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7234292 (ISIS 443139) IN HUNTINGTON'S DISEASE PATIENTS WHO PARTICIPATED IN PRIOR INVESTIGATIONAL STUDIES OF RO7234292 (ISIS 443139) Early Manifest Huntington's Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Code: Ro 723-4292/F02
INN or Proposed INN: n.a.
Other descriptive name: RG6042, formerly ISIS 443139, IONIS-HTTRx
F.Hoffmann La-Roche LtdNULLNot RecruitingFemale: yes
Male: yes
46Phase 1;Phase 2Canada;Germany;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41NCT03575676
(ClinicalTrials.gov)
August 8, 201811/6/2018Efficacy and Safety of SOM3355 in Huntington's Disease ChoreaPhase IIa, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of SOM3355 in Huntington's Disease (HD) Patients With Chorea Movements.Huntington's ChoreaDrug: SOM3355 100mg BID;Drug: SOM3355 200mg BID;Drug: Placebo BIDSOM Biotech SLNULLCompleted18 YearsN/AAll32Phase 2Spain
42EUCTR2016-005142-39-GB
(EUCTR)
02/08/201819/05/2017A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s Disease Huntington’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Wave Life Sciences UK LimitedNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
48Phase 1;Phase 2France;United States;Canada;Poland;Denmark;Australia;Germany;United Kingdom
43EUCTR2016-005095-10-GB
(EUCTR)
02/08/201817/10/2017A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease Huntington's Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Wave Life Sciences UK LimitedNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
60Phase 1;Phase 2France;United States;Canada;Poland;Denmark;Australia;Germany;United Kingdom
44NCT02509793
(ClinicalTrials.gov)
August 1, 201824/7/2015A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)Huntington's DiseaseDrug: TetrabenazineWilliam Ondo, MDH. Lundbeck A/SRecruiting18 Years80 YearsAll20Phase 4United States
45EUCTR2018-000203-16-ES
(EUCTR)
18/06/201821/05/2018Phase IIa, double-blind, randomized, placebo-controlled study of the efficacy and safety of SOM3335 in Huntington`s disease (HD) patients with chorea movements.Phase IIa, double-blind, randomized, placebo-controlled study of the efficacy and safety of SOM3335 in Huntington`s disease (HD) patients with chorea movements. Chorea movements associated with Huntington's Disease
MedDRA version: 20.0;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
SOM BiotechNULLNot Recruiting Female: yes
Male: yes
30Phase 2Spain
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
46NCT03713892
(ClinicalTrials.gov)
May 23, 201817/10/2018CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female SubjectsPhase I Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, PK, PD of CKD-504 in Single SAD and MAD in Healthy Korean and Caucasian Adult Male and Female SubjectsHuntington DiseaseDrug: CKD-504;Drug: PlaceboChong Kun Dang PharmaceuticalNULLRecruiting19 Years45 YearsAll88Phase 1Korea, Republic of
47NCT03252535
(ClinicalTrials.gov)
January 15, 201815/8/2017Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's DiseaseDose-Response Evaluation of the Investigational Product Cellavita HD After Intravenous Administration in Patients With Huntington's DiseaseHuntington DiseaseBiological: Cellavita HD lower dose;Biological: Cellavita HD higher dose;Other: PlaceboAzidus BrasilCellavita Pesquisa Científica LtdaActive, not recruiting21 Years65 YearsAll35Phase 2Brazil
48EUCTR2017-002471-25-DE
(EUCTR)
10/01/201807/08/2017An extension study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the study drug, RO7234292 (ISIS 443139), in patients who participated in prior investigational studies of RO7234292An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington’s Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139) Early Manifest Huntington's Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Code: Ro 723-4292/F02
INN or Proposed INN: n.a.
Other descriptive name: RG6042, formerly ISIS 443139, IONIS-HTTRx
F.Hoffmann La-Roche LtdNULLNot RecruitingFemale: yes
Male: yes
46Phase 2Canada;Germany;United Kingdom
49NCT03342053
(ClinicalTrials.gov)
November 27, 201731/10/2017A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)Huntington's DiseaseDrug: RO7234292 (RG6042)Hoffmann-La RocheNULLCompleted25 YearsN/AAll46Phase 2Canada;Germany;United Kingdom
50NCT02728115
(ClinicalTrials.gov)
October 16, 201711/3/2016Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's DiseaseFirst in Human Study to Evaluate Safety of Cellavita HD Investigational Product After Intravenous Application in Participants With Huntington's DiseaseHuntington DiseaseBiological: Cellavita HD Lower Dose;Biological: Cellavita HD Higher doseAzidus BrasilCellavita Pesquisa Científica Ltda;Azidus Brasil Scientific Research and Development LtdaActive, not recruiting21 Years65 YearsMale6Phase 1Brazil
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
51NCT03296176
(ClinicalTrials.gov)
October 9, 201715/9/2017Metabolomic Study in Huntington's Disease (METABO-HD)Metabolomic Study in Huntington's DiseaseHuntington DiseaseBiological: blood sampleUniversity Hospital, AngersNULLRecruiting20 Years70 YearsAll150N/AFrance
52NCT03225846
(ClinicalTrials.gov)
July 17, 201717/7/2017Safety and Tolerability of WVE-120102 in Patients With Huntington's DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients With Huntington's DiseaseHuntington's DiseaseDrug: WVE-120102;Drug: PlaceboWave Life Sciences Ltd.NULLRecruiting25 Years65 YearsAll60Phase 1;Phase 2Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
53NCT03225833
(ClinicalTrials.gov)
July 17, 201717/7/2017Safety and Tolerability of WVE-120101 in Patients With Huntington's DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients With Huntington's DiseaseHuntington's DiseaseDrug: WVE-120101;Drug: PlaceboWave Life Sciences Ltd.NULLRecruiting25 Years65 YearsAll60Phase 1;Phase 2Australia;Canada;Denmark;France;Germany;Poland;United Kingdom
54NCT03515213
(ClinicalTrials.gov)
April 27, 20172/8/2017Safety and Efficacy of Fenofibrate as a Treatment for Huntington's DiseaseA Phase IIa, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Fenofibrate as a Treatment for Huntington's DiseaseHuntington DiseaseDrug: Fenofibrate;Drug: PlaceboUniversity of California, IrvineNULLActive, not recruiting18 YearsN/AAll20Phase 2United States
55NCT03019289
(ClinicalTrials.gov)
April 19, 20173/1/2017A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's DiseaseA Phase I, Open-Label, Single-Dose, Adaptive (S)-(-)-[18F]Fluspidine and [18F]Fallypride Positron Emission Tomography Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's DiseaseHealth Volunteers, Huntington DiseaseDrug: pridopidine (90 mg)PrileniaNULLCompleted25 YearsN/AMale23Phase 1Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
56EUCTR2016-003730-25-NL
(EUCTR)
14/02/201709/01/2017A study to assess the safety and efficacy of a new medicine SBT-020 in patients with Early Stage Huntington’s Disease.A Two Part Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SBT-020 in Patients with Early Stage Huntington’s Disease. - SBT-020 in HD Huntington's Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: SBT-020
Product Code: SBT-020
INN or Proposed INN: SBT-020
Other descriptive name: SS-20
Stealth Bio Therapeutics IncNULLNot RecruitingFemale: yes
Male: yes
24Phase 2Netherlands
57NCT02507284
(ClinicalTrials.gov)
May 10, 201622/7/2015Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's DiseaseAn Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)Irritable Mood;Huntington's DiseaseDrug: SRX246;Drug: PlaceboAzevan PharmaceuticalsNational Institute of Neurological Disorders and Stroke (NINDS);NeuroNEXT NetworkCompleted18 YearsN/AAll106Phase 2United States
58NCT02994719
(ClinicalTrials.gov)
March 1, 201621/12/2015Gait Analysis in Neurological DiseaseGait Pattern Analysis in Neurological DiseaseParkinson's Disease;Parkinsonian Disorders;Atypical Parkinson Disease;Progressive Supranuclear Palsy;Multiple System Atrophy;Corticobasal Degeneration;Gait, Frontal;Huntington DiseaseDrug: Anti-Parkinson medication;Device: Deep Brain StimulationBeth Israel Deaconess Medical CenterNULLActive, not recruiting18 Years85 YearsAll120United States
59NCT02907294
(ClinicalTrials.gov)
March 20168/3/2016Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 After Multiple Oral Doses in Healthy VolunteersRandomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 (160 mg and 320 mg) After Multiple Oral Doses in Healthy VolunteersHuntington DiseaseDrug: PBF-999 / 160 mg;Drug: PBF-999 / 320 mg;Drug: PlaceboPalobiofarma SLFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauTerminated18 Years45 YearsBoth8Phase 1Spain
60EUCTR2015-000904-24-NL
(EUCTR)
15/02/201617/02/2016A study testing if pridopidine is safe and efficacious in patients with Huntington's DiseaseA Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease - Open PRIDE-HD Huntington's disease
MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Pridopidine
Product Code: TV-7820
INN or Proposed INN: pridopidine
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Product Name: Pridopidine
Product Code: TV-7820
INN or Proposed INN: pridopidine
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Teva Branded Pharmaceutical Products R&D, IncNULLNot RecruitingFemale: yes
Male: yes
300Phase 2France;United States;Canada;Poland;Denmark;Austria;Australia;Russian Federation;Germany;Netherlands;Italy;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
61EUCTR2014-005112-42-NL
(EUCTR)
11/12/201507/08/2015A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3)A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3) Huntington's disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Product Name: Triheptanoin
Product Code: UX007
INSERMNULLNot RecruitingFemale: yes
Male: yes
100Phase 2France;Netherlands
62EUCTR2015-000904-24-DE
(EUCTR)
03/12/201504/08/2015A study testing if pridopidine is safe and efficacious in patients with Huntington's DiseaseA Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease - Open PRIDE-HD Huntington's disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Pridopidine
Product Code: TV-7820
INN or Proposed INN: pridopidine
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Product Name: Pridopidine
Product Code: TV-7820
INN or Proposed INN: pridopidine
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Teva Branded Pharmaceutical Products R&D, IncNULLNot RecruitingFemale: yes
Male: yes
300Phase 2Poland;Austria;Australia;France;United States;Canada;Russian Federation;Netherlands;Germany;Italy;United Kingdom
63EUCTR2015-000904-24-AT
(EUCTR)
18/11/201515/09/2015A study testing if pridopidine is safe and efficacious in patients with Huntington's DiseaseA Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease - Open PRIDE-HD Huntington's disease
MedDRA version: 19.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Pridopidine
Product Code: TV-7820
INN or Proposed INN: pridopidine
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Product Name: Pridopidine
Product Code: TV-7820
INN or Proposed INN: pridopidine
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Teva Branded Pharmaceutical Products R&D, IncNULLNot RecruitingFemale: yes
Male: yes
300Phase 2France;United States;Canada;Poland;Denmark;Australia;Austria;Russian Federation;Netherlands;Germany;Italy;United Kingdom
64EUCTR2015-000904-24-GB
(EUCTR)
13/11/201518/08/2015A study testing if pridopidine is safe and efficacious in patients with Huntington's DiseaseA Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease - Open PRIDE-HD Huntington's disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Teva Branded Pharmaceutical Products R&D, IncNULLNot Recruiting Female: yes
Male: yes
300Phase 2France;United States;Canada;Poland;Austria;Australia;Russian Federation;Netherlands;Germany;Italy;United Kingdom
65EUCTR2014-000418-75-NL
(EUCTR)
04/11/201515/10/2014A clinical study in subjects with Huntington's Disease to assess the efficacy and safety of three oral doses of laquinimod, either 0.5 mg/day, 1.0 mg/day or 1.5 mg/day (experimental drug)A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease - LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD) Huntington's Disease (HD)
MedDRA version: 18.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Laquinimod capsules 0.5 mg
Product Code: TV-5600
INN or Proposed INN: LAQUINIMOD
Other descriptive name: 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium
Teva Branded Pharmaceutical Products R&D, Inc.NULLNot RecruitingFemale: yes
Male: yes
330Phase 2Portugal;United States;Czech Republic;Canada;Spain;Russian Federation;Germany;Netherlands;Italy;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
66NCT02494778
(ClinicalTrials.gov)
September 24, 20157/7/2015A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's DiseaseA Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease (Open PRIDE-HD)Huntington's DiseaseDrug: PridopidinePrileniaNULLTerminated21 YearsN/AAll248Phase 2United States;Australia;Austria;Canada;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom;Denmark
67EUCTR2015-000904-24-IT
(EUCTR)
15/09/201523/02/2018A study testing if pridopidine is safe and efficacious in patients with Huntington's DiseaseA Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington's Disease - Open PRIDE-HD Huntington's disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Pridopidina
Product Code: TV-7820
INN or Proposed INN: Pridopidina
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Product Name: Pridopidina
Product Code: TV-7820
INN or Proposed INN: Pridopidina
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INCNULLNot RecruitingFemale: yes
Male: yes
400Phase 2France;United States;Canada;Poland;Denmark;Austria;Australia;Russian Federation;Netherlands;Germany;United Kingdom;Italy
68NCT02519036
(ClinicalTrials.gov)
August 6, 20151/8/2015Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's DiseaseA Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 443139 in Patients With Early Manifest Huntington's DiseaseHuntington's DiseaseDrug: ISIS 443139 10 mg;Drug: ISIS 443139 30 mg;Drug: ISIS 443139 60 mg;Drug: ISIS 443139 90 mg;Drug: ISIS 443139 120 mg;Other: PlaceboIonis Pharmaceuticals, Inc.NULLCompleted25 Years65 YearsAll46Phase 1;Phase 2Canada;Germany;United Kingdom
69NCT02336633
(ClinicalTrials.gov)
July 20158/1/2015Resveratrol and Huntington DiseaseMetabolic Intervention Using Resveratrol in Patients With Huntington DiseaseHuntington DiseaseDietary Supplement: Resveratrol;Other: PlaceboAssistance Publique - Hôpitaux de ParisNULLCompleted18 YearsN/AAll102N/AFrance
70NCT02481674
(ClinicalTrials.gov)
July 201519/6/2015A Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Pepinemab (VX15/2503)A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503Huntington's DiseaseDrug: VX15/2503;Drug: PlaceboVaccinex Inc.Huntington Study GroupCompleted21 YearsN/AAll301Phase 2United States;Canada
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
71NCT02453061
(ClinicalTrials.gov)
June 29, 201512/5/2015A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's DiseaseA Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's DiseaseHuntington DiseaseDrug: Triheptanoin oil;Drug: PlaceboInstitut National de la Santé Et de la Recherche Médicale, FranceUltragenyx Pharmaceutical IncActive, not recruiting18 YearsN/AAll100Phase 2France;Netherlands
72EUCTR2014-005112-42-FR
(EUCTR)
22/06/201522/06/2015A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3)A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3) Huntington's disease
MedDRA version: 18.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders
Product Name: Triheptanoin
Product Code: UX007
INSERMNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 2France;Netherlands
73EUCTR2014-004900-31-DE
(EUCTR)
27/05/201513/02/2015AN OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY, TOLERABILITY AND EFFICACY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE WHO PREVIOUSLY COMPLETED STUDY A8241021AN OPEN LABEL EXTENSION STUDY TO INVESTIGATE THE LONG TERM SAFETY, TOLERABILITY AND EFFICACY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE WHO PREVIOUSLY COMPLETED STUDY A8241021 HUNTINGTON'S DISEASE
MedDRA version: 17.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 17.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: PF-02545920
INN or Proposed INN: not available
Other descriptive name: PF-02545920
Pfizer Inc, 235 East 42nd Street, New York, NY 10017NULLNot RecruitingFemale: yes
Male: yes
260Phase 2United States;Canada;Poland;Germany;United Kingdom
74EUCTR2014-001291-56-GB
(EUCTR)
24/04/201521/07/2014A PHASE 2, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PROOF-OF-CONCEPT STUDY OF THE EFFICACY AND SAFETY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASEA PHASE 2, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PROOF-OF-CONCEPT STUDY OF THE EFFICACY AND SAFETY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE HUNTINGTON’S DISEASE
MedDRA version: 17.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 17.0;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Pfizer Inc., 235 East 42nd Street, New York, NY 10017NULLNot Recruiting Female: yes
Male: yes
260Phase 2United States;Canada;Poland;Germany;United Kingdom
75EUCTR2013-001888-23-DK
(EUCTR)
13/04/201508/01/2015A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease.A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease Huntington’s disease
MedDRA version: 17.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Pridopidine
Product Code: TV-7820
INN or Proposed INN: pridopidine
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Product Name: Pridopidine
Product Code: TV-7820
INN or Proposed INN: pridopidine
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Teva Branded Pharmaceutical Products R&D, IncNULLNot RecruitingFemale: yes
Male: yes
400Phase 2United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Denmark;Australia;Germany;Netherlands
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
76NCT02342548
(ClinicalTrials.gov)
February 25, 201515/1/2015Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021An Open Label Extension Study To Investigate The Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Previously Completed Study A8241021Huntington's DiseaseDrug: 20 mg BID of PF-02545920PfizerNULLTerminated30 Years66 YearsAll188Phase 2United States;Canada;Germany;Poland;United Kingdom
77EUCTR2014-000418-75-GB
(EUCTR)
30/01/201524/09/2014A clinical study in subjects with Huntington's Disease to assess the efficacy and safety of three oral doses of laquinimod, either 0.5 mg/day, 1.0 mg/day or 1.5 mg/day (experimental drug)A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease - LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD) Huntington's Disease (HD)
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Teva Branded Pharmaceutical Products R&D, Inc.NULLNot Recruiting Female: yes
Male: yes
330Phase 2Portugal;United States;Czech Republic;Canada;Spain;Russian Federation;Netherlands;Germany;Italy;United Kingdom
78EUCTR2014-000418-75-DE
(EUCTR)
06/01/201525/09/2014A clinical study in subjects with Huntington's Disease to assess the efficacy and safety of three oral doses of laquinimod, either 0.5 mg/day, 1.0 mg/day or 1.5 mg/day (experimental drug)A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease - LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD) Huntington's Disease (HD)
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Laquinimod capsules 0.5 mg
Product Code: TV-5600
INN or Proposed INN: LAQUINIMOD
Other descriptive name: 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium
Teva Branded Pharmaceutical Products R&D, Inc.NULLNot RecruitingFemale: yes
Male: yes
330Phase 2Portugal;United States;Czech Republic;Canada;Spain;Russian Federation;Netherlands;Germany;Italy;United Kingdom
79EUCTR2014-000418-75-CZ
(EUCTR)
05/01/201525/09/2014A clinical study in subjects with Huntington's Disease to assess the efficacy and safety of three oral doses of laquinimod, either 0.5 mg/day, 1.0 mg/day or 1.5 mg/day (experimental drug)A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease - LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD) Huntington's Disease (HD)
MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Laquinimod capsules 0.5 mg
Product Code: TV-5600
INN or Proposed INN: LAQUINIMOD
Other descriptive name: 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium
Teva Branded Pharmaceutical Products R&D, Inc.NULLNot RecruitingFemale: yes
Male: yes
330Phase 2Portugal;United States;Czech Republic;Canada;Spain;Russian Federation;Netherlands;Germany;Italy;United Kingdom
80EUCTR2014-000418-75-IT
(EUCTR)
18/11/201425/08/2014A clinical study in subjects with Huntington's Disease to assess the efficacy and safety of three oral doses of laquinimod, either 0.5 mg/day, 1.0 mg/day or 1.5 mg/day (experimental drug)A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease - LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD) Huntington's Disease (HD)
MedDRA version: 17.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Laquinimod capsules 0.5 mg
Product Code: TV-5600
INN or Proposed INN: LAQUINIMOD
Other descriptive name: 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium
Teva Branded Pharmaceutical Products R&D, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
400Portugal;France;United States;Czech Republic;Canada;Spain;Netherlands;Germany;United Kingdom;Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
81EUCTR2014-000418-75-PT
(EUCTR)
31/10/201425/09/2014A clinical study in subjects with Huntington's Disease to assess the efficacy and safety of three oral doses of laquinimod, either 0.5 mg/day, 1.0 mg/day or 1.5 mg/day (experimental drug)A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease - LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD) Huntington's Disease (HD)
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Teva Branded Pharmaceutical Products R&D, Inc.NULLNot Recruiting Female: yes
Male: yes
330Phase 2United States;Portugal;Czech Republic;Canada;Spain;Russian Federation;Netherlands;Germany;Italy;United Kingdom
82NCT02215616
(ClinicalTrials.gov)
October 28, 201412/8/2014A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of LaquinimodA Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's DiseaseHuntington's DiseaseDrug: Laquinimod;Drug: PlaceboTeva Branded Pharmaceutical Products R&D, Inc.NULLCompleted21 Years55 YearsAll352Phase 2United States;Canada;Czechia;Germany;Italy;Netherlands;Portugal;Russian Federation;Spain;United Kingdom;Czech Republic;France;India;Israel
83EUCTR2014-001291-56-DE
(EUCTR)
27/10/201418/07/2014A PHASE 2, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PROOF-OF-CONCEPT STUDY OF THE EFFICACY AND SAFETY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASEA PHASE 2, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLIND PROOF-OF-CONCEPT STUDY OF THE EFFICACY AND SAFETY OF PF-02545920 IN SUBJECTS WITH HUNTINGTON’S DISEASE HUNTINGTON’S DISEASE
MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 19.0;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: PF-02545920
INN or Proposed INN: not available
Other descriptive name: PF-02545920
Pfizer Inc, 235 East 42nd Street, New York, NY 10017NULLNot RecruitingFemale: yes
Male: yes
260Phase 2United States;Canada;Poland;Germany;United Kingdom
84EUCTR2014-000418-75-ES
(EUCTR)
23/10/201416/10/2014A clinical study in subjects with Huntington's Disease to assess the efficacy and safety of three oral doses of laquinimod, either 0.5 mg/day, 1.0 mg/day or 1.5 mg/day (experimental drug)A Multicenter, Multinational, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease - LEGATO-HD (Laquinimod Efficacy and Safety in a GlobAl Trial Of HD) Huntington's Disease (HD)
MedDRA version: 17.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Laquinimod capsules 0.5 mg
Product Code: TV-5600
INN or Proposed INN: LAQUINIMOD
Other descriptive name: 5-Chloro-1,2-dihydro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-3-quinolinecarboxamide sodium
Teva Branded Pharmaceutical Products R&D, Inc.NULLNot RecruitingFemale: yes
Male: yes
400Phase 2Portugal;France;United States;Czech Republic;Canada;Spain;Netherlands;Germany;Italy;United Kingdom
85NCT02231580
(ClinicalTrials.gov)
September 1, 20142/9/2014Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease PatientsA Dose Escalation, Proof of Concept, Phase IIa Study to Investigate the Safety and Tolerability, the Pharmacokinetic and the Pharmacodynamic of BN82451B, Administered Twice Daily Over 4 Weeks, in Male Patients With Huntington's DiseaseHuntington's DiseaseDrug: BN82451B;Drug: PlaceboIpsenNULLTerminated20 Years70 YearsMale17Phase 2Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
86NCT02208934
(ClinicalTrials.gov)
September 20144/8/2014Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male VolunteersStudy To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male VolunteersHuntington's DiseaseDrug: PBF-999;Drug: PlaceboFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauPalo Biofarma, S.LCompleted18 Years45 YearsMale32Phase 1Spain
87NCT02197130
(ClinicalTrials.gov)
September 201416/7/2014Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's DiseaseA Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's DiseaseHuntington's DiseaseDrug: PF-02545920;Other: PlaceboPfizerNULLCompleted30 Years65 YearsAll272Phase 2United States;Canada;Germany;Poland;United Kingdom
88NCT01834053
(ClinicalTrials.gov)
September 201411/4/2013Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea.Safety and Efficacy of Bone Marrow Derived MNCs for the Treatment of Huntingtons Chorea. It is Self Funded (Patients' Own Funding) Clinical TrialHuntington DiseaseBiological: autologous Stem CellChaitanya Hospital, PuneNULLRecruiting35 Years44 YearsBoth50Phase 1;Phase 2India
89EUCTR2013-001888-23-PL
(EUCTR)
23/07/201414/05/2014A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease.A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease Huntington’s disease
MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Pridopidine
Product Code: TV-7820
INN or Proposed INN: pridopidine
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Product Name: Pridopidine
Product Code: TV-7820
INN or Proposed INN: pridopidine
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Teva Branded Pharmaceutical Products R&D, IncNULLNot RecruitingFemale: yes
Male: yes
400Phase 2United States;Austria;Russian Federation;Italy;United Kingdom;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands
90EUCTR2013-001888-23-AT
(EUCTR)
01/07/201408/01/2014A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease.A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease Huntington’s disease
MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Pridopidine
Product Code: TV-7820
INN or Proposed INN: pridopidine
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Product Name: Pridopidine
Product Code: TV-7820
INN or Proposed INN: pridopidine
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Teva Branded Pharmaceutical Products R&D, IncNULLNot RecruitingFemale: yes
Male: yes
400Phase 2United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
91EUCTR2013-002899-41-DE
(EUCTR)
28/04/201424/01/2014Study to assess the effects of BN82451B and how it is absorbed, distributed and eliminated in the body, when it is given for 4 weeks to men suffering from Hungtington's diseaseA dose escalation, proof of concept, phase IIa study to investigate the safety and tolerability, the pharmacokinetic and thepharmacodynamic of BN82451B, administered twice daily over 4 weeks, in male patients with Huntington’s disease Huntington's disease
MedDRA version: 18.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: BN8251B
INN or Proposed INN: N/A
Other descriptive name: BN82451B
Product Name: BN8251B
INN or Proposed INN: N/A
Other descriptive name: BN82451B
Ipsen PharmaNULLNot RecruitingFemale: no
Male: yes
Phase 2Germany
92EUCTR2013-001888-23-NL
(EUCTR)
07/04/201420/12/2013A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease.A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease Huntington’s disease
MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Pridopidine
Product Code: TV-7820
INN or Proposed INN: pridopidine
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Product Name: Pridopidine
Product Code: TV-7820
INN or Proposed INN: pridopidine
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Teva Branded Pharmaceutical Products R&D, IncNULLNot RecruitingFemale: yes
Male: yes
400Phase 2United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Netherlands;Germany
93EUCTR2013-001888-23-DE
(EUCTR)
25/03/201410/12/2013A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease.A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease Huntington’s disease
MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Pridopidine
Product Code: TV-7820
INN or Proposed INN: pridopidine
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Product Name: Pridopidine
Product Code: TV-7820
INN or Proposed INN: pridopidine
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Teva Branded Pharmaceutical Products R&D, IncNULLNot RecruitingFemale: yes
Male: yes
400Phase 2United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands
94EUCTR2013-001888-23-IT
(EUCTR)
13/03/201411/12/2013A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease.A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease Huntington’s disease
MedDRA version: 14.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Pridopidine
Product Code: TV-7820
INN or Proposed INN: pridopidine
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Product Name: Pridopidine
Product Code: TV-7820
INN or Proposed INN: pridopidine
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Teva Branded Pharmaceutical Products R&D, IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
400Phase 2United States;Austria;Russian Federation;Italy;United Kingdom;France;Czech Republic;Canada;Poland;Australia;Denmark;Netherlands;Germany
95NCT02006472
(ClinicalTrials.gov)
February 28, 20145/12/2013A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's DiseaseA Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's DiseaseHuntington's DiseaseDrug: Pridopidine;Other: PlaceboPrileniaEuropean Huntington's Disease Network;Huntington Study GroupCompleted21 YearsN/AAll408Phase 2United States;Australia;Austria;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Russian Federation;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
96EUCTR2013-001888-23-GB
(EUCTR)
22/01/201427/11/2013A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease.A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease Huntington’s disease
MedDRA version: 17.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Pridopidine
Product Code: TV-7820
INN or Proposed INN: pridopidine
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Product Name: Pridopidine
Product Code: TV-7820
INN or Proposed INN: pridopidine
Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826
Teva Branded Pharmaceutical Products R&D, IncNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
400Phase 2United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands
97EUCTR2013-002545-10-SE
(EUCTR)
08/01/201411/11/2013An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g Parkinson’s disease, Huntington’s disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy.An open safety study with the monoaminergic stabilizer (-)-OSU6162 in patients with mental fatigue and related vitality and wakefulness disturbances associated with neurologiacal disorders, e g Parkinson’s disease, Huntington’s disease, brain trauma, stroke, myalgic encephalomyelitis and narcolepsy. - OSU6162Open1309 Parkinsons diseaseHuntingtons diseaseMultiple sclerosBrain traumaStrokeMyalgic encephalomyelitisNarcolepsy;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Code: OSU6162 similar to (-)-OSU 6162A. Carlsson Research ABNULLNot RecruitingFemale: yes
Male: yes
240Phase 2Sweden
98NCT02074410
(ClinicalTrials.gov)
January 201421/2/2014Safety and Efficacy of OMS643762 in Subjects With Huntington's DiseasePhase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of OMS643762 in Subjects With Huntington's DiseaseHuntington's DiseaseDrug: OMS643762;Drug: PlaceboOmeros CorporationNULLTerminated18 Years65 YearsAll22Phase 2United States
99NCT01897896
(ClinicalTrials.gov)
November 12, 201314/6/2013Alternatives for Reducing Chorea in Huntington DiseaseAn Open-Label, Long Term Safety Study of SD-809 ER in Subjects With Chorea Associated With Huntington DiseaseChorea Associated With Huntington DiseaseDrug: SD-809Auspex Pharmaceuticals, Inc.NULLCompleted18 YearsN/AAll119Phase 3United States;Australia;Canada
100NCT01806896
(ClinicalTrials.gov)
September 20136/3/2013Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's DiseaseA Phase 2, Double-blind Randomized, Sequential Treatment Group, Placebo-controlled Study To Evaluate The Safety, Tolerability And Brain Cortico-striatal Function Of 2 Doses Of Pf-02545920 In Subjects With Early Huntington's DiseaseHuntington's DiseaseDrug: PF-02545920;Drug: PlaceboPfizerNULLCompleted18 Years70 YearsAll37Phase 2France
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
101NCT01795859
(ClinicalTrials.gov)
August 5, 201320/2/2013First Time Use of SD-809 in Huntington DiseaseA Randomized Double-Blind, Placebo-Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington DiseaseChoreaDrug: SD-809;Drug: PlaceboTeva Pharmaceutical IndustriesNULLCompleted18 YearsN/AAll90Phase 3United States;Australia;Canada
102NCT01882062
(ClinicalTrials.gov)
May 201318/6/2013Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington DiseaseHuntington DiseaseDrug: Triheptanoin 1g/kg/dayInstitut National de la Santé Et de la Recherche Médicale, FranceNULLCompleted18 YearsN/AAll10Phase 2France
103NCT01834911
(ClinicalTrials.gov)
March 201315/4/2013Effect of Tetrabenazine on Stroop Interference in HDEffect of Tetrabenazine on Stroop Interference in Huntington DiseaseHuntington DiseaseDrug: Tetrabenazine withdrawalNew York Medical CollegeNULLCompleted18 YearsN/AAll2Phase 4United States
104NCT01696708
(ClinicalTrials.gov)
December 6, 201220/9/2012Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington DiseaseStudy of the Brain Energy Profile Evolution, Using 31Phosphorus-Nuclear Magnetic Resonance Spectroscopy, at Different Stages of Huntington DiseaseHuntington DiseaseOther: 31-Phosphorus RMN SpectroscopyInstitut National de la Santé Et de la Recherche Médicale, FranceNULLCompleted18 YearsN/AAll50N/AFrance
105NCT01914965
(ClinicalTrials.gov)
June 201231/7/2013Apathy Cure Through Bupropion in Huntington's DiseaseA Randomized, Double-blind, Placebo-controlled Prospective Crossover Trial Investigating the Efficacy and Safety of the Treatment With Bupropion in Patients With Apathy in Huntington's DiseaseApathy;Huntington's DiseaseDrug: Bupropion;Drug: PlaceboCharite University, Berlin, GermanyUniversity of Ulm;Ruhr University of Bochum;University Hospital MuensterCompleted25 Years75 YearsBoth40Phase 2Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
106NCT01590888
(ClinicalTrials.gov)
April 201218/4/2012Effect of PBT2 in Patients With Early to Mid Stage Huntington DiseaseA Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, and Efficacy of PBT2 in Patients With Early to Mid-stage Huntington DiseaseHuntington DiseaseDrug: PBT2;Drug: PlaceboPrana Biotechnology LimitedNULLCompleted25 YearsN/AAll109Phase 2United States;Australia
107NCT01573819
(ClinicalTrials.gov)
November 24, 201116/2/2012A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278A Randomised, Placebo Controlled, Ascending, Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278Huntington DiseaseDrug: GSK356278;Drug: PlaceboGlaxoSmithKlineNULLCompleted18 Years65 YearsAll36Phase 1Netherlands
108NCT01602900
(ClinicalTrials.gov)
November 22, 20111/12/2011Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's DiseaseAn Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain PDE4 Engagement, Pharmacokinetics and Safety of Single Oral Doses of GSK356278, Using 11C-(R)-Rolipram as a PET Ligand(s)Huntington DiseaseDrug: GSK356278;Drug: RolipramGlaxoSmithKlineNULLCompleted22 Years55 YearsMale8Phase 1United Kingdom
109NCT01485965
(ClinicalTrials.gov)
November 201129/11/2011A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington DiseaseA Phase 1b, Open-label, Parallel-group Study in Subjects With Huntington Disease to Assess the Safety, Tolerability, and Fed/Fasted Pharmacokinetics of Repeated Oral Doses of SEN0014196Huntington's DiseaseDrug: SEN0014196Siena Biotech S.p.A.NULLCompleted25 Years65 YearsBoth26Phase 1United States
110NCT01521585
(ClinicalTrials.gov)
November 201126/1/2012A Phase II Safety and Tolerability Study With SEN0014196A Double-blind, Placebo-controlled Study in Huntington's Disease Patients to Determine the Safety and Tolerability of SEN0014196Huntington's DiseaseDrug: SEN0014196;Drug: PlaceboSiena Biotech S.p.A.NULLCompleted30 Years70 YearsBoth144Phase 2Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
111EUCTR2011-001131-23-GB
(EUCTR)
24/10/201118/07/2011A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease.A double-blind, placebo-controlled study in Huntington’s Disease patients to determine the safety and tolerability of SEN0014196 - N/A Huntington's disease
MedDRA version: 14.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: SEN0014196
Product Code: SEN0014196
INN or Proposed INN: selisistat
Product Name: SEN0014196
Product Code: SEN0014196
INN or Proposed INN: selisistat
Siena Biotech SpANULLNot RecruitingFemale: yes
Male: yes
144Germany;Italy;United Kingdom
112EUCTR2011-001131-23-IT
(EUCTR)
20/10/201122/11/2011A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease.A double-blind, placebo-controlled study in Huntington's Disease patients to determine the safety and tolerability of SEN0014196 Huntington's disease
MedDRA version: 14.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 14.0;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: SEN0014196
Product Code: SEN0014196
INN or Proposed INN: selisistat
Product Name: SEN0014196
Product Code: SEN0014196
INN or Proposed INN: selisistat
SIENA BIOTECH SPANULLNot RecruitingFemale: yes
Male: yes
144Germany;United Kingdom;Italy
113EUCTR2011-001131-23-DE
(EUCTR)
21/09/201127/06/2011A study to determine how safe and tolerable the study drug is, when given to patients with Huntingtons Disease.A double-blind, placebo-controlled study in Huntington’s Disease patients to determine the safety and tolerability of SEN0014196 - N/A Huntington's disease
MedDRA version: 14.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: SEN0014196
Product Code: SEN0014196
INN or Proposed INN: selisistat
Product Name: SEN0014196
Product Code: SEN0014196
INN or Proposed INN: selisistat
Siena Biotech SpANULLNot RecruitingFemale: yes
Male: yes
144Germany;Italy;United Kingdom
114NCT01357681
(ClinicalTrials.gov)
September 201119/5/2011Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease The ETON-Study - A Randomized, Double-blind, Stratified, Placebo-controlled Prospective Investigator Initiated Multicenter Trial -Huntington DiseaseDrug: (2)-epigallocatechin-3-gallate (EGCG);Drug: PlaceboCharite University, Berlin, GermanyNULLCompleted18 YearsN/ABoth54Phase 2Germany
115NCT01502046
(ClinicalTrials.gov)
September 201129/12/2011Neuroprotection by Cannabinoids in Huntington's DiseaseA Double Blind, Randomized, Cross Over, Placebo Controlled Phase 2 Clinical Trial to Asses Neuroprotection by Cannabinoids in Huntington's DiseaseHuntington's DiseaseDrug: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD);Drug: PlaceboFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalGW Pharmaceuticals Ltd.Completed18 YearsN/ABoth25Phase 2Spain
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
116NCT01458470
(ClinicalTrials.gov)
September 201120/10/2011A Trial of Memantine as Symptomatic Treatment for Early Huntington DiseaseA Trial of Memantine as Symptomatic Treatment for Early Huntington Disease; a Phase IIb StudyHuntington DiseaseDrug: Memantine;Other: PlaceboUniversity of British ColumbiaHuntington Society of Canada;Huntington Study GroupCompleted18 Years75 YearsAll19Phase 2Canada
117NCT01306929
(ClinicalTrials.gov)
March 1, 201128/2/2011Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington DiseaseA Multi-Center, North American, Open-Label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington's Disease (Open-HART).Huntington DiseaseDrug: pridopidinePrileniaNULLCompletedN/AN/AAll235Phase 2United States;Canada
118NCT01485952
(ClinicalTrials.gov)
March 201129/11/2011An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients With SEN0014196An Exploratory Clinical Trial in Early Stage Huntington's Disease Patients to Assess Pharmacokinetics, Candidate Pharmacodynamic Measures of Target Engagement and Disease Modulation as Well as Acute Phenotypical Effects Following Multiple Oral Doses of SEN0014196.Huntington DiseaseDrug: SEN0014196 (Low Dose);Drug: SEN0014196 (High Dose);Drug: PlaceboSiena Biotech S.p.A.Seventh Framework Programme;European Huntington's Disease NetworkCompleted18 Years70 YearsBoth55Phase 1Germany
119NCT02101957
(ClinicalTrials.gov)
October 201025/3/2014Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)Huntington's DiseaseDrug: RP103;Drug: PlaceboUniversity Hospital, AngersNULLActive, not recruiting18 Years65 YearsBoth96Phase 2;Phase 3France
120EUCTR2009-018123-32-SE
(EUCTR)
30/09/201010/06/2010HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-PlusHORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus Huntington disease
MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Medivation, IncNULLNot RecruitingFemale: yes
Male: yes
350United Kingdom;Germany;Netherlands;Denmark;Italy;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
121EUCTR2009-018123-32-NL
(EUCTR)
23/08/201014/04/2010HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-PlusHORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus Huntington disease
MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Medivation, IncNULLNot RecruitingFemale: yes
Male: yes
350United Kingdom;Germany;Netherlands;Denmark;Italy;Sweden
122EUCTR2009-018123-32-IT
(EUCTR)
28/07/201015/07/2010HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease(Protocol DIM20EXT) - Horizon-PlusHORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease(Protocol DIM20EXT) - Horizon-Plus Huntington`s Corea
MedDRA version: 9.1;Level: LLT;Classification code 10020469
Product Name: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Product Name: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
MEDIVATION, INC.NULLNot RecruitingFemale: yes
Male: yes
350United Kingdom;Germany;Netherlands;Denmark;Italy;Sweden
123EUCTR2009-018119-14-GB
(EUCTR)
23/07/201018/06/2010Huntington's Disease Rilmenidine Safety Trial - Huntington's Disease Rilmenidine studyHuntington's Disease Rilmenidine Safety Trial - Huntington's Disease Rilmenidine study Huntington's Disease
MedDRA version: 14.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders
Cambridge University Hospitals NHS Foundation Trust and University of CambridgeNULLNot Recruiting Female: yes
Male: yes
16Phase 2United Kingdom
124EUCTR2010-019444-39-FR
(EUCTR)
18/06/201004/05/2010Essai multicentrique de traitement de la maladie de Huntington par la cystéamine - CYST-HDEssai multicentrique de traitement de la maladie de Huntington par la cystéamine - CYST-HD Maladie de Huntington.
MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: Cysteamine Bitartrate
Product Code: RP 103
Centre Hospitalier Universitaire d'AngersNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
France
125EUCTR2009-018123-32-DE
(EUCTR)
07/06/201002/03/2010HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-PlusHORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus Huntington disease
MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Medivation, IncNULLNot RecruitingFemale: yes
Male: yes
350Denmark;Netherlands;Germany;Italy;United Kingdom;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
126EUCTR2009-018123-32-GB
(EUCTR)
14/05/201018/03/2010HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-PlusHORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus Huntington disease
MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Medivation, IncNULLNot RecruitingFemale: yes
Male: yes
350Germany;United Kingdom;Netherlands;Denmark;Italy;Sweden
127EUCTR2009-018123-32-DK
(EUCTR)
23/04/201016/03/2010HORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-PlusHORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects with Huntington Disease - HORIZON-Plus Huntington disease
MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Medivation, IncNULLNot RecruitingFemale: yes
Male: yes
350United Kingdom;Germany;Netherlands;Denmark;Italy;Sweden
128NCT01411163
(ClinicalTrials.gov)
April 20104/8/2011Premanifest Huntington's Disease Extension Study II: Creatine Safety & TolerabilityPremanifest Huntington's Disease Extension Study II: Creatine Safety & TolerabilityHuntington's DiseaseDrug: Creatine monohydrateMassachusetts General HospitalNational Institutes of Health (NIH)Completed26 YearsN/ABoth24Phase 2United States
129NCT01085266
(ClinicalTrials.gov)
February 201010/3/2010An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington DiseaseHORIZON-Plus: An Open-Label Extension of the HORIZON Protocol (DIM20) Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington DiseaseHuntington DiseaseDrug: Dimebon (latrepirdine)Medivation, Inc.Pfizer;PfizerTerminated30 YearsN/ABoth362Phase 3NULL
130NCT00920699
(ClinicalTrials.gov)
February 20109/6/2009Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)A Multi-Center, Double-Blind, Randomized, Parallel Group Tolerability Study of Coenzyme Q10 (UbiquinonE)in PRE-manifest Huntington's DiseaseHuntington's DiseaseDrug: CoQ10Johns Hopkins UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Completed18 YearsN/AAll90Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
131EUCTR2009-011800-44-NL
(EUCTR)
20/01/201028/09/2009A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZONA Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZON Huntington disease
MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Medivation, IncNULLNot RecruitingFemale: yes
Male: yes
350Phase 3Germany;United Kingdom;Netherlands;Denmark;Italy;Sweden
132EUCTR2009-011800-44-IT
(EUCTR)
22/12/200904/11/2009A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease Version 2.0 08 May 2009 - DIM20A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease Version 2.0 08 May 2009 - DIM20 Patients with Mild-to-Moderate Huntington Disease
MedDRA version: 12.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: Dimebon
Product Name: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
MEDIVATION, INC.NULLNot RecruitingFemale: yes
Male: yes
350Phase 3Germany;United Kingdom;Netherlands;Denmark;Italy;Sweden
133EUCTR2009-011743-39-GB
(EUCTR)
15/12/200921/08/2009A multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration Proof of Concept study in patients with Huntington's disease to assess the efficacy, safety and tolerability of AFQ056 in reducing choreaA multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration Proof of Concept study in patients with Huntington's disease to assess the efficacy, safety and tolerability of AFQ056 in reducing chorea Huntington's disease
MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: AFQ056
Product Code: AFQ056
Product Name: AFQ056
Product Code: AFQ056
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
64Germany;United Kingdom
134EUCTR2009-011800-44-SE
(EUCTR)
14/12/200923/09/2009A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZONA Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZON Huntington disease
MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Medivation, IncNULLNot RecruitingFemale: yes
Male: yes
350Phase 3Germany;United Kingdom;Netherlands;Denmark;Italy;Sweden
135NCT01019473
(ClinicalTrials.gov)
November 200919/11/2009Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing ChoreaA Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Titration Proof of Concept Study in Patients With Huntington's Disease to Assess the Efficacy, Safety and Tolerability of AFQ056 in Reducing ChoreaHuntington's Disease;ChoreaDrug: AFQ056;Drug: PlaceboNovartis PharmaceuticalsNULLTerminated30 Years85 YearsBoth44Phase 2Germany;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
136EUCTR2009-011800-44-DE
(EUCTR)
07/10/200906/07/2009A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZONA Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZON Huntington disease
MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Medivation, IncNULLNot RecruitingFemale: yes
Male: yes
350Phase 3Denmark;Netherlands;Germany;Italy;United Kingdom;Sweden
137EUCTR2009-011800-44-GB
(EUCTR)
07/10/200905/06/2009A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZONA Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZON Huntington disease
MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Medivation, IncNULLNot RecruitingFemale: yes
Male: yes
350Phase 3Germany;United Kingdom;Netherlands;Denmark;Italy;Sweden
138NCT00990613
(ClinicalTrials.gov)
October 20096/10/2009A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The SkinA Phase 1, Fixed Sequence, Cross-Over Study To Investigate The Single Dose Pharmacokinetics Of A Dimebon (Latrepirdine) Transdermal Solution Relative To The Immediate Release Formulation In Older AdultsAlzheimer's Disease;Huntington's DiseaseDrug: Dimebon IR;Drug: Dimebon TransdermalPfizerMedivation, Inc.Completed50 Years85 YearsBoth19Phase 1United States
139NCT00988624
(ClinicalTrials.gov)
October 20091/10/2009A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)A Phase 1, Randomized, Open-Label, Single Dose Cross-Over Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)Alzheimer's Disease;Huntington DiseaseDrug: Dimebon IR Tablet;Drug: Dimebon MR1;Drug: Dimebon MR2;Drug: Dimebon MR3;Drug: Dimebon MR4PfizerMedivation, Inc.Completed18 Years55 YearsBoth20Phase 1United States
140NCT01521832
(ClinicalTrials.gov)
October 200913/1/2012Escalating Dose Study in Healthy Volunteers With SEN0014196A Phase I, Randomised, Double-Blind, Placebo-Controlled, Two-Part Study Consisting of Single and Multiple Oral Dose Escalation to Determine, Safety, Tolerability and Pharmacokinetics of SEN0014196Huntington's DiseaseDrug: SEN0014196Siena Biotech S.p.A.NULLCompleted18 Years65 YearsBoth88Phase 1United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
141NCT00975481
(ClinicalTrials.gov)
October 200910/9/2009A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug UsersA Randomized, Double-Blind, Placebo- And Active-Controlled Single-Dose, Crossover Study To Evaluate The Abuse Potential Of Single Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug UsersAlzheimer's Disease;Huntington's DiseaseDrug: dimebon;Drug: placebo;Drug: alprazolamPfizerMedivation, Inc.Completed18 Years55 YearsAll36Phase 1Canada
142EUCTR2009-011743-39-DE
(EUCTR)
18/09/200920/08/2009Efficacy, Safety and Tolerability of AFQ056 in Patients with Huntington's Disease in Reducing ChoreaA multi-centre, randomized, double-blind, placebo-controlled, parallel-group, multiple oral dose titration Proof of Concept study in patients with Huntington's disease to assess the efficacy, safety and tolerability of AFQ056 in reducing chorea Huntington's disease
MedDRA version: 13.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: AFQ056
Product Code: AFQ056
Product Name: AFQ056
Product Code: AFQ056
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
60United States;Germany;United Kingdom
143EUCTR2009-011800-44-DK
(EUCTR)
11/09/200904/08/2009A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZONA Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease - HORIZON Huntington disease
MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Product Name: Dimebon
Product Code: Dimebon
INN or Proposed INN: Dimebon dihydrochloride
Other descriptive name: Dimebon dihydrochloride
Medivation, IncNULLNot RecruitingFemale: yes
Male: yes
350Phase 3Germany;United Kingdom;Netherlands;Denmark;Italy;Sweden
144NCT00712426
(ClinicalTrials.gov)
September 20098/7/2008Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)Huntington's DiseaseDrug: Creatine Monohydrate;Drug: PlaceboMassachusetts General HospitalUniversity of Rochester;National Center for Complementary and Integrative Health (NCCIH)Terminated18 YearsN/ABoth553Phase 3United States;Australia;Canada;New Zealand
145NCT00980694
(ClinicalTrials.gov)
September 200917/9/2009Bioavailability of Ubiquinol in Huntington DiseaseBioavailability of Ubiquinol in Huntington DiseaseHuntington DiseaseDietary Supplement: ubiquinolUniversity of RochesterKaneka CorporationCompleted18 YearsN/ABoth6Phase 1United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
146NCT00970229
(ClinicalTrials.gov)
July 200931/8/2009Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in Subjects With Parkinson Disease, Huntington Disease, and Healthy ControlsParkinson Disease;Huntington DiseaseDrug: [123I]MNI-420Institute for Neurodegenerative DisordersNULLCompleted18 YearsN/AAll19Phase 1United States
147NCT00931073
(ClinicalTrials.gov)
July 20091/7/2009A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 MetabolizersA Phase I, Open-Label, Three-Period, Fixed-Sequence Study To Estimate The Steady-State Effect Of Ketoconazole And Omeprazole On The Single-Dose Pharmacokinetics Of Dimebon [PF-01913539] In Healthy CYP2D6 EM And PM SubjectsAlzheimer's Disease;Huntington's DiseaseDrug: Dimebon alone;Drug: Dimebon + Ketoconazole;Drug: Dimebon + OmeprazolePfizerMedivation, Inc.Completed18 Years55 YearsBoth24Phase 1United States
148NCT00920946
(ClinicalTrials.gov)
July 200912/6/2009A Safety and Efficacy Study of Dimebon in Patients With Huntington DiseaseA Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients With Mile-to-Moderate Huntington DiseaseHuntington DiseaseDrug: Dimebon;Other: PlaceboMedivation, Inc.Pfizer;PfizerCompleted30 YearsN/ABoth403Phase 3United States;Australia;Canada;Denmark;Germany;Sweden;United Kingdom
149NCT00907595
(ClinicalTrials.gov)
May 200920/5/2009Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With RamelteonTreating Sleep Wake Cycle Disturbances in Basal Ganglia Neurodegenerative Disorder Subjects With Ramelteon- A Double Blind, Placebo Controlled TrialHuntington's Disease;Parkinson's Disease;Dementia With Lewy Bodies;Sleep Disorders;Circadian DysregulationDrug: Ramelteon;Drug: PlaceboMassachusetts General HospitalNULLWithdrawn20 Years90 YearsBoth0N/AUnited States
150NCT01411150
(ClinicalTrials.gov)
May 20094/8/2011Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension StudyPremanifest Huntington's Disease: Creatine Safety & Tolerability Extension StudyHuntington's DiseaseDrug: Creatine MonohydrateMassachusetts General HospitalNational Institutes of Health (NIH)Completed26 YearsN/ABoth38Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
151EUCTR2007-004988-22-AT
(EUCTR)
02/04/200919/02/2008A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008)A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) Huntington's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: ACR16
Product Code: ACR16
NeuroSearch Sweden ABNULLNot RecruitingFemale: yes
Male: yes
420Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria
152NCT00632645
(ClinicalTrials.gov)
April 200929/2/2008Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and TiaprideNeuroleptic and Huntington Disease. Comparison of : Olanzapine, la Tetrabenazine and Tiapride. A Multicentric, Randomised, Controlled Study.Huntington DiseaseDrug: Olanzapine;Drug: Xenazine;Drug: TiapridalAssistance Publique - Hôpitaux de ParisNULLCompleted18 YearsN/AAll180Phase 3France
153NCT00870974
(ClinicalTrials.gov)
March 200926/3/2009A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric ConditionsEvaluation of [18F]PEB and Positron Emission Tomography (PET) as a Marker of mGluR5 in Subjects w/ Neuropsychiatric ConditionsParkinson Disease;Huntington Disease;Autistic Spectrum Disorders;Fragile X Syndrome;Alzheimer Disease;Mild Cognitive ImpairmentDrug: [18F]FPEBInstitute for Neurodegenerative DisordersNULLCompleted18 Years85 YearsAll48Phase 1United States
154NCT00824590
(ClinicalTrials.gov)
February 200912/1/2009A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal FunctionA Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal FunctionAlzheimer's Disease;Huntington's DiseaseDrug: DimebonPfizerMedivation, Inc.Completed18 Years75 YearsBoth20Phase 1United States
155NCT00825084
(ClinicalTrials.gov)
February 200912/1/2009A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy SubjectsA Phase 1, Randomized, Subject- And Investigator-Blind, Sponsor-Open, Placebo-Controlled, Parallel-Cohort, Single-Dose Escalation, And Multiple-Dose Titration Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy SubjectsAlzheimer's Disease;Huntington's DiseaseDrug: DimebonPfizerMedivation, Inc.Completed18 Years55 YearsBoth45Phase 1United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
156NCT00827034
(ClinicalTrials.gov)
February 200920/1/2009A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy SubjectsA Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy SubjectsAlzheimer's Disease;Huntington's DiseaseDrug: Warfarin;Drug: DimebonPfizerMedivation, Inc.Completed18 Years55 YearsAll14Phase 1United States
157NCT00831506
(ClinicalTrials.gov)
February 200927/1/2009Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy SubjectsA Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF-01913539) On The Safety, Tolerability, And Steady-State Pharmacokinetics Of Digoxin In Healthy SubjectsAlzheimer Disease;Huntington DiseaseDrug: digoxin;Drug: dimebonPfizerMedivation, Inc.Completed18 Years55 YearsBoth12Phase 1United States
158NCT00788047
(ClinicalTrials.gov)
November 20087/11/2008A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of DextromethorphanA Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon [PF-01913539] On The Single-Dose Pharmacokinetics Of The CYP2D6 Substrate Dextromethorphan In Healthy SubjectsHuntington Disease;Alzheimer DiseaseDrug: Dextromethorphan;Drug: Dimebon + DextromethorphanPfizerMedivation, Inc.Completed18 Years55 YearsBoth14Phase 1United States
159NCT00724048
(ClinicalTrials.gov)
October 200824/7/2008A Study of Pridopidine (ACR16) for the Treatment of Patients With Huntington's DiseaseA Multi-center, North American, Randomized, Double-blind, Parallel Group Study Comparing Three Doses of ACR16 Versus Placebo for the Symptomatic Treatment of Huntington Disease (HART)Huntington DiseaseDrug: ACR16 10 mg;Drug: ACR16 22.5 mg;Drug: ACR16 45 mg;Other: PlaceboTeva Pharmaceutical IndustriesNULLCompleted30 YearsN/ABoth227Phase 2;Phase 3United States;Canada
160EUCTR2007-002977-30-FR
(EUCTR)
02/09/200828/08/2008Essai multicentrique évaluant l'effet de la cystéamine sur le BDNF sérique dans la maladie de Huntington. - BDNF-HDEssai multicentrique évaluant l'effet de la cystéamine sur le BDNF sérique dans la maladie de Huntington. - BDNF-HD Maladie de Huntigton (MH): maladie neurodégénérative d’origine génétique. Elle associe des troubles moteurs, psychiatriques et cognitifs (dégénérescence neuronale dans le striatum). Aucun traitement validé n’existe à ce jour.
MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Trade Name: CYSTAGON
Product Name: CYSTAGON
Centre Hospitalier Universitaire d'AngersNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
France
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
161EUCTR2007-004988-22-IT
(EUCTR)
26/08/200829/07/2008A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington?s Disease - NDA multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington?s Disease - ND Huntington's DiseaseProduct Code: ACR16NEUROSEARCH SWEDEN ABNULLNot RecruitingFemale: yes
Male: yes
420Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria
162EUCTR2007-004988-22-PT
(EUCTR)
06/06/200814/02/2008A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008)A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) Huntington's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: ACR16
Product Code: ACR16
NeuroSearch Sweden ABNULLNot RecruitingFemale: yes
Male: yes
420Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria
163EUCTR2007-004988-22-ES
(EUCTR)
03/06/200811/02/2008Un estudio multicentro, internacional, aleatorizado, doble ciego y de grupos paralelos que compara la administración de ACR16 45 mg una o dos veces al día frente al placebo, para el tratamiento sintomático de la Enfermedad de Huntington.(A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease) - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008)Un estudio multicentro, internacional, aleatorizado, doble ciego y de grupos paralelos que compara la administración de ACR16 45 mg una o dos veces al día frente al placebo, para el tratamiento sintomático de la Enfermedad de Huntington.(A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease) - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) Enfermedad de Huntington (Huntington's Disease)
MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: ACR16
Product Code: ACR16
NeuroSearch Sweden ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
420Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria
164EUCTR2007-004988-22-FR
(EUCTR)
23/05/200808/01/2008A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008)A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) Huntington's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: ACR16
Product Code: ACR16
NeuroSearch Sweden ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
420Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria
165NCT00665223
(ClinicalTrials.gov)
April 200822/4/2008A Study of Treatment With Pridopidine (ACR16) in Patients With Huntington's DiseaseA Multicentre, Multinational, Randomized, Double-blind, Parallel-group Study Comparing ACR16 Versus Placebo for the Symptomatic Treatment of Huntington's DiseaseHuntington's DiseaseDrug: ACR16;Drug: PlaceboTeva Pharmaceutical IndustriesNULLCompleted30 YearsN/ABoth437Phase 3Austria;Belgium;France;Germany;Italy;Portugal;Spain;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
166NCT00608881
(ClinicalTrials.gov)
March 20084/2/2008Coenzyme Q10 in Huntington's Disease (HD)Coenzyme Q10 in Huntington's Disease (HD)Huntington's DiseaseDrug: coenzyme Q10;Other: placeboMassachusetts General HospitalNational Institute of Neurological Disorders and Stroke (NINDS);University of RochesterTerminated16 YearsN/AAll609Phase 3United States;Australia;Canada
167EUCTR2007-004988-22-DE
(EUCTR)
22/02/200826/10/2007A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008)A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) Huntington's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: ACR16
Product Code: ACR16
NeuroSearch Sweden ABNULLNot RecruitingFemale: yes
Male: yes
420Portugal;France;Spain;Belgium;Austria;Germany;Italy;United Kingdom
168EUCTR2007-004988-22-GB
(EUCTR)
11/01/200816/10/2007A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008)A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) Huntington's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: ACR16
Product Code: ACR16
NeuroSearch Sweden ABNULLNot RecruitingFemale: yes
Male: yes
420Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria
169EUCTR2007-004988-22-BE
(EUCTR)
04/01/200830/10/2007A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008)A multicentre, multinational, randomised, double-blind, parallel-group study comparing ACR16 45mg once-daily or twice-daily versus placebo for the symptomatic treatment of Huntington’s Disease - A Study of Treatment with ACR16 in Patients with Huntington's Disease (ACR16 C008) Huntington's Disease
MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Product Name: ACR16
Product Code: ACR16
NeuroSearch Sweden ABNULLNot RecruitingFemale: yes
Male: yes
420Portugal;Germany;United Kingdom;Belgium;France;Spain;Italy;Austria
170NCT00592995
(ClinicalTrials.gov)
December 200728/12/2007Creatine Safety and Tolerability in Premanifest HD: PRECRESTCreatine Safety and Tolerability in Premanifest HD: PRECRESTHuntington DiseaseDrug: Creatine monohydrate;Drug: PlaceboMassachusetts General HospitalNULLCompleted26 YearsN/ABoth64Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
171EUCTR2007-003293-25-GB
(EUCTR)
20/11/200726/07/2007A MULTI-CENTER, PHASE 2 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF DIMEBON IN SUBJECTS WITH HUNTINGTON’S DISEASE - DIMONDA MULTI-CENTER, PHASE 2 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF DIMEBON IN SUBJECTS WITH HUNTINGTON’S DISEASE - DIMOND Huntington's disease
MedDRA version: 9.1;Level: LLT;Classification code 10020469;Term: Huntington's chorea
Medivation, Inc.NULLNot Recruiting Female: yes
Male: yes
90Phase 2United Kingdom
172NCT00514774
(ClinicalTrials.gov)
August 20078/8/2007Ursodiol in Huntington's DiseaseUrsodiol in Huntington's DiseaseHuntington DiseaseDrug: ursodiol;Drug: placeboOregon Health and Science UniversityHuntington Study Group;Huntington Society of CanadaActive, not recruiting18 YearsN/ABoth21Phase 1United States
173NCT00497159
(ClinicalTrials.gov)
July 20073/7/2007A Study of the Novel Drug Dimebon in Patients With Huntington's DiseaseA Multi-Center, Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's DiseaseHuntington's DiseaseOther: Placebo;Drug: DimebonMedivation, Inc.Huntington Study GroupCompleted29 YearsN/ABoth90Phase 2United States
174NCT00387270
(ClinicalTrials.gov)
October 200610/10/2006Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's DiseaseA Multicenter, Phase 1-2A, Open-Label, Dosage-Escalation and Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's DiseaseHuntington's DiseaseDrug: DimebonMedivation, Inc.Huntington Study GroupCompleted18 YearsN/ABoth9Phase 1;Phase 2United States
175EUCTR2005-002088-98-PT
(EUCTR)
07/06/200616/03/2006Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s DiseaseFull title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease HUNTINGTON’S DISEASE
MedDRA version: 8.0;Level: LLT;Classification code 10010331
Product Name: Ethyl-EPA
Product Code: LAX-101
INN or Proposed INN: Ethyl Icosapent
Other descriptive name: Ethyl-EPA
Amarin Neuroscience LtdNULLNot RecruitingFemale: yes
Male: yes
Portugal;Germany;United Kingdom;Spain;Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
176NCT00277355
(ClinicalTrials.gov)
April 200612/1/2006Pilot Study of Minocycline in Huntington's DiseaseA Multi-Center, Double-Blind, Pilot Study of Minocycline in Huntington's DiseaseHuntington DiseaseDrug: minocycline;Drug: Matching placeboMerit CudkowiczFDA Office of Orphan Products DevelopmentCompleted18 YearsN/AAll114Phase 2;Phase 3United States;Canada
177EUCTR2005-002088-98-ES
(EUCTR)
29/12/200504/10/2005Full title of the trial : Estudio multicentrico, multinacional aleatorizado doble ciego con grupos paralelos y controlado con placebo de etil-EPA (etil eicosapentanoato) en pacientes con enfermedad de Huntington.Full title of the trial : Estudio multicentrico, multinacional aleatorizado doble ciego con grupos paralelos y controlado con placebo de etil-EPA (etil eicosapentanoato) en pacientes con enfermedad de Huntington. HUNTINGTON’S DISEASE
MedDRA version: 8.0;Level: llt;Classification code 10010331
Product Name: Ethyl-EPA
Product Code: LAX-101
Amarin Neuroscience LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Portugal;Germany;United Kingdom;Spain;Italy
178EUCTR2005-002088-98-AT
(EUCTR)
01/12/200527/10/2005Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s DiseaseFull title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease HUNTINGTON’S DISEASE
MedDRA version: 8.0;Level: LLT;Classification code 10010331
Product Name: Ethyl-EPA
Product Code: LAX-101
INN or Proposed INN: Ethyl-Icosapent
Amarin Neuroscience LtdNULLNot RecruitingFemale: yes
Male: yes
240Portugal;Spain;Austria;Germany;Italy;United Kingdom
179EUCTR2005-002088-98-GB
(EUCTR)
07/11/200518/08/2005Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s DiseaseFull title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease HUNTINGTON’S DISEASE
MedDRA version: 8.0;Level: LLT;Classification code 10010331
Product Name: Ethyl-EPA
Product Code: LAX-101
Amarin Neuroscience LtdNULLNot RecruitingFemale: yes
Male: yes
Portugal;Germany;United Kingdom;Spain;Italy
180NCT00271596
(ClinicalTrials.gov)
November 200530/12/2005Citalopram to Enhance Cognition in HDA Randomized, Placebo-Controlled Pilot Study in Huntington's Disease (CIT-HD)Huntington Disease;Chorea;Executive DysfunctionDrug: 20mg daily citalopram;Drug: PlaceboUniversity of IowaNational Institute of Neurological Disorders and Stroke (NINDS);Cure Huntington's Disease Initiative (CHDI);University of Rochester;Mayo ClinicCompleted18 Years75 YearsAll33Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
181NCT00368849
(ClinicalTrials.gov)
November 200524/8/2006Atomoxetine and Huntington's DiseaseAtomoxetine for Attention Deficits in Adults With Mild HD: A Randomized, Placebo-Controlled Crossover StudyHuntington Disease;ChoreaDrug: atomoxetine;Drug: Matching PlaceboUniversity of IowaEli Lilly and CompanyCompleted18 Years65 YearsAll20Phase 2United States
182NCT00146211
(ClinicalTrials.gov)
September 20052/9/2005TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's DiseaseA Multicenter, Double Blind, Randomized, Parallel Group, Placebo-Controlled Trial of Ethyl-EPA (Miraxion™) in Subjects With Mild to Moderate Huntington's DiseaseHuntington DiseaseDrug: Ethyl-EPA (Miraxion™)Amarin Neuroscience LtdHuntington Study GroupCompleted35 YearsN/ABoth300Phase 3United States;Canada
183NCT00212316
(ClinicalTrials.gov)
August 200519/9/2005Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)Phenylbutyrate Development for Huntington's Disease (PHEND-HD): A Multi-Center, Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up to Determine the Safety and Tolerability of Phenylbutyrate in Subjects With Huntington's DiseaseHuntington's DiseaseDrug: sodium phenylbutyrateUniversity of RochesterHP Therapeutics Foundation;Massachusetts General Hospital;Columbia University;University of Iowa;University of California, San Diego;University of Kansas;University of Alabama at Birmingham;Johns Hopkins UniversityCompleted18 YearsN/ABoth60Phase 2United States
184NCT01412151
(ClinicalTrials.gov)
April 20055/8/2011Creatine Safety & Tolerability in Huntington's DiseaseCreatine Safety & Tolerability in Huntington's Disease (CREST-X): A Single-Center, Open-Label, Long-Term Safety & Tolerability Extension Study of Creatine in Subjects With HDHuntington's Disease (HD)Drug: Creatine monohydrateMassachusetts General HospitalNULLCompleted18 YearsN/AAll10Phase 2United States
185NCT00652457
(ClinicalTrials.gov)
November 23, 200431/3/2008Study of Memantine to Treat Huntington's DiseaseA Pilot Study of Memantine for Cognitive and Behavioral Dysfunction in Huntington's DiseaseHuntington's DiseaseDrug: MemantineJody Corey-Bloom, MD, PhDForest LaboratoriesCompleted18 YearsN/AAll60Phase 4United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
186EUCTR2004-000394-60-DK
(EUCTR)
05/10/200417/08/2004A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington diseaseA randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington disease ACR16 belongs to a new class of CNS active agents called dopaminergic stabilizers. Dopaminergic stabilizers are compounds that can both enhance and counteract dopamine dependent functions in the CNS, depending on the initial level of dopaminergic activity. The stabilizing feature of such compounds is illustrated by their interaction with dopaminergic agonists.Product Name: ACR16
Product Code: ACR16
A. Carlsson Research ABNULLNot RecruitingFemale: yes
Male: yes
60Phase 2Denmark;Sweden
187NCT00095355
(ClinicalTrials.gov)
October 20042/11/2004Effects of Lithium and Divalproex`on Brain-Derived Neurotrophic Factor in Huntington's DiseaseStimulation of Tyrosine Kinase and ERK Signaling Pathways in Huntington's DiseaseHuntington's DiseaseDrug: Lithium;Drug: DivalproexNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth35Phase 2United States
188EUCTR2004-000394-60-SE
(EUCTR)
30/06/200413/05/2004A randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington diseaseA randomised phase II multicentre, double blind, parallel group, placebo controlled study of ACR16 50 mg once daily for the symptomatic treatment of Huntington disease ACR16 belongs to a new class of CNS active agents called dopaminergic stabilizers. Dopaminergic stabilizers are compounds that can both enhance and counteract dopamine dependent functions in the CNS, depending on the initial level of dopaminergic activity. The stabilizing feature of such compounds is illustrated by their interaction with dopaminergic agonists.Product Name: ACR16
Product Code: ACR16
A. Carlsson Research ABNULLNot RecruitingFemale: yes
Male: yes
60Phase 2Denmark;Sweden
189NCT00190450
(ClinicalTrials.gov)
January 200215/9/2005MIG-HD: Multicentric Intracerebral Grafting in Huntington's DiseaseMulticentric Intracerebral Grafting in Huntington's DiseaseHuntington DiseaseBiological: graft intracerebral of foetal neuronsAssistance Publique - Hôpitaux de ParisNULLCompleted18 Years65 YearsAll54Phase 2France
190NCT00026988
(ClinicalTrials.gov)
October 200115/11/2001Creatine Therapy for Huntington's DiseaseCreatine Therapy for Huntington's DiseaseHuntington's DiseaseDrug: CreatineNational Center for Complementary and Integrative Health (NCCIH)NULLCompleted18 YearsN/ABoth64Phase 1;Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
191NCT00029874
(ClinicalTrials.gov)
September 200124/1/2002Minocycline in Patients With Huntington's DiseaseMinocycline Dosing and Safety in Huntington's DiseaseHuntington's DiseaseDrug: MinocyclineFDA Office of Orphan Products DevelopmentNULLCompleted18 YearsN/ABoth63Phase 1;Phase 2United States
192NCT00219804
(ClinicalTrials.gov)
January 200014/9/2005Efficacy and Safety of Tetrabenazine in ChoreaA Randomized, Double-Blind, Placebo-Controlled Study of Tetrabenazine for the Treatment of Huntington's ChoreaHuntington's DiseaseDrug: tetrabenazine or placeboPrestwick PharmaceuticalsNULLCompleted18 YearsN/ABothPhase 3NULL
193NCT00277602
(ClinicalTrials.gov)
November 199913/1/2006Riluzole in Huntington's DiseaseA Phase III Multicenter, Double-Blind, Parallel-Group, Placebo Controlled Study to Measure the Effect of Riluzole 50 mg b.i.d. Over a Period of Three Years on the Progression of Huntington's DiseaseHuntington DiseaseDrug: RiluzoleSanofiNULLCompleted25 Years65 YearsBoth537Phase 3NULL
194NCT00001930
(ClinicalTrials.gov)
April 19993/11/1999Treatment of Huntington's Chorea With AmantadineNMDA-Receptor Blockade in Huntington's ChoreaChorea;Huntington's DiseaseDrug: AmantadineNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth25Phase 2United States
195EUCTR2016-005142-39-DE
(EUCTR)
04/06/2019A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients with Huntington’s Disease Huntington’s Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120102
Product Code: WVE-120102
INN or Proposed INN: WVE-120102
Wave Life Sciences UK LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
80Phase 1;Phase 2France;United States;Canada;Poland;Denmark;Australia;Germany;United Kingdom
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
196EUCTR2016-005095-10-DE
(EUCTR)
04/06/2019A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s DiseaseA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients with Huntington’s Disease Huntington's Disease
MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: WVE-120101
Product Code: WVE-120101
INN or Proposed INN: WVE-120101
Wave Life Sciences UK LimitedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 1;Phase 2France;Canada;Poland;Denmark;Australia;Germany;United Kingdom
197EUCTR2005-002088-98-DE
(EUCTR)
28/11/2006Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s DiseaseFull title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease HUNTINGTON’S DISEASE
MedDRA version: 8.0;Level: LLT;Classification code 10010331
Product Name: Ethyl-EPA
Product Code: LAX-101
INN or Proposed INN: Ethyl-Icosapent
Amarin Neuroscience LtdNULLNot RecruitingFemale: yes
Male: yes
240Portugal;United Kingdom;Germany;Spain;Italy